We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lonza to Expand ADC Manufacturing Capacity
News

Lonza to Expand ADC Manufacturing Capacity

Lonza to Expand ADC Manufacturing Capacity
News

Lonza to Expand ADC Manufacturing Capacity

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lonza to Expand ADC Manufacturing Capacity"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lonza has announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland.

Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.

Because cGMP manufacturing of ADCs presents unique challenges, facilities must be designed to handle both biological species and highly potent cytotoxic small molecule drugs.

Lonza has been a pioneer in the manufacturing of ADCs since its initial investment in 2006 which established manufacturing suites for both small and large scale projects, dedicated Research & Development labs, and Quality Control facilities specifically for ADCs.

Since 2010, Lonza has validated large scale manufacturing of platform technologies primarily utilized by ADC drug developers.

The expansion of the ADC facility will double the existing large-scale manufacturing capacity in Visp while allowing current operations to continue without interruption.

It is the next step in bringing challenging new technologies to one of Lonza’s main sites.

The capacity expansion, expected to be complete in the second quarter of 2014, has the potential to bring new job opportunities across all functions in Visp.

“We have witnessed significant growth in the ADC market in the past 24 months and this investment is necessary to continue to support the growing product demands from our customers” said Stefan Stoffel, Head of Lonza’s Chemical Manufacturing business unit.

Stoffel continued, “Lonza Visp will continue to offer a fully integrated end-to-end development and manufacturing solution for ADCs, including the cytotoxic small molecules used in these products and all associated analytics. In addition, Lonza can support protein development and manufacturing via our global biologics development and manufacturing sites.”

Lonza’s continued investment to increase ADC capacity and highly trained personnel allows its customers to capitalize on the unique infrastructure of the Visp site and limit their own investment in the expertise, assets, and infrastructure required to work with these highly potent biological products in a highly regulated environment.

Advertisement